Nasdaq nmra.

Fiscal Q3 2023 ended 9/30/23. Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed...Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... Neumora Therapeutics Inc. (NASDAQ: NMRA) grossed $250.1 million in a September initial public offering that was due in part to a drug pipeline that includes an experimental schizophrenia drug that ...Visualize o gráfico de Neumora Therapeutics, Inc. ao vivo para acompanhar o movimento do preço de suas ações. Encontre previsões de mercado, NMRA finanças e notícias do mercado.On Invalid Date, . Neumora Therapeutics (NASDAQ: NMRA) reported Q3 2023 earnings per share (EPS) of -$1.14, up 7.55% year over year. Total Neumora Therapeutics earnings for the quarter were -$53.03 million.In the same quarter last year, Neumora Therapeutics's earnings per share (EPS) was -$1.06.

Nov 24, 2023 · Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ... Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com.Common Stock stock price (NMRA). NASDAQ: NMRA. Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you ...

View NMRA historial stock data and compare to other stocks and exchanges. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). On Invalid Date, . Neumora Therapeutics (NASDAQ: NMRA) reported Q3 2023 earnings per share (EPS) of -$1.14, up 7.55% year over year. Total Neumora Therapeutics earnings for the quarter were -$53.03 million.In the same quarter last year, Neumora Therapeutics's earnings per share (EPS) was -$1.06.Nov 27, 2023 · 1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, expenses and ... WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …

Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

Encontre o valor de abertura e fechamento das cotações NMRA para ficar atualizado sobre as tendências do mercado financeiro. Compartilhe sua visão de mercado, interaja com …

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Veja o histórico completo das cotações para Neumora Therapeutics Inc, consulte informações sobre o preço de fechamento, de abertura, máximas, mínimas e as …NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ...Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric …WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.NASDAQ:NMRA; Company Type For Profit. Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain ...

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Sep 21, 2023 · Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. Neumora Therapeutics, Inc. ( Nasdaq: NMRA), visits the Nasdaq MarketSite in Times Square. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global ...Neumora Therapeutics (NASDAQ: NMRA) · Neumora Therapeutics Return vs. S&P · Neumora Therapeutics Company Info · News & Analysis · Financial Health · Valuation.Insiders and Institutions Are Buying These Robot Stocks. This page (NASDAQ:NMRA) was last updated on 11/24/2023 by MarketBeat.com Staff. Adding. Choose a ...

Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .

Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...How much institutional buying is happening at Neumora Therapeutics? Institutional investors have bought a total of 11,743,056 shares in the last 24 months. This purchase volume represents approximately $165.69M in transactions. This page (NASDAQ:NMRA) was last updated on 11/28/2023 by MarketBeat.com Staff.Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines. WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company …What happenedShares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The ...Veja o histórico completo das cotações para Neumora Therapeutics Inc, consulte informações sobre o preço de fechamento, de abertura, máximas, mínimas e as …Sep 21, 2023 · Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.

Nov 29, 2023 · markets.businessinsider.com - November 27 at 10:19 AM. Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. finance.yahoo.com - November 27 at 10:19 AM. Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $11.69. americanbankingnews.com - November 24 at 5:19 AM.

NVDA. NVIDIA Corporation Common Stock. $439.00 -16.81 -3.69%. Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com.

Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …Neumora (NASDAQ: NMRA) develops precision medicines to restore brain health. It focuses on discovering, developing, and commercializing targeted therapies for people living with brain diseases. The company was founded in …6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On …Nasdaq | NMRA U.S.: Nasdaq Neumora Therapeutics Inc. Watch list NEW Set a price target alert After Hours Last Updated: Oct 4, 2023 7:35 p.m. EDT Delayed quote $ 12.27 0.36 3.02% After Hours... Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO.Shares of the psychiatric drug developer opened ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...Neumora Therapeutics Inc (NMRA). NASDAQ. Create Alert. Create Alert. New! Create Alert. Website. As an alert notification; To use this feature, make sure you ...Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Dec 2, 2023 · Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) – Investment analysts at William Blair decreased their FY2023 earnings estimates for Neumora Therapeutics in a report issued on Monday, November 27th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($4.25) per share for the year, down from their previous estimate of […] Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...

NMRA Neumora Therapeutics Inc Form 8-K - Current report false 0001885522 0001885522 2023-11-01 2023-11-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT R...Neumora Therapeutics, Inc. (NASDAQ:NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended SEC registration statement.Neumora Therapeutics (NASDAQ: NMRA) · Neumora Therapeutics Return vs. S&P · Neumora Therapeutics Company Info · News & Analysis · Financial Health · Valuation.Instagram:https://instagram. urnm dividendmaybach 600prologis dividendafrican yen Neumora hopes to list its shares on Nasdaq under the symbol NMRA. JP Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are serving a joint bookrunners. www.triconresidentialwhaup Based on analysts offering 12 month price targets for NMRA in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. broker ratings Oct 10, 2023 · In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease. For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.